Bevacizumab, Aflibercept Reduce Macular Edema

Two new studies show that bevacizumab and aflibercept can reduce macular edema and improve visual acuity in patients with central retinal vein occlusion (CRVO). The two drugs block vascular endothelial growth factor (VEGF), as appeared in Ophthalmology.

Visual acuity in the bevacizumab group improved by a mean of 7.5 letters at 6 weeks. 11.4 letters at 12 weeks, 13.9 letters at 18 weeks, and 14.1 letters at 24 weeks. More patients in the bevacizumab group had no residual edema at 24 weeks.

In a second study using aflibercept, at week 24 56.1% of eyes treated had gained 15 letters or more from baseline. Macular edema declined to a significantly greater extent with aflibercept than with a sham treatment.

No serious adverse events with bevacizumab, but there was one case each of endophthalmitis, maculopathy, ocular discomfort, and retinal artery occlusion attributed to aflibercept treatment.


One thought on “Bevacizumab, Aflibercept Reduce Macular Edema

Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s